RBC Capital analyst Luca Issi reiterates Beam Therapeutics (NASDAQ:BEAM) with a Sector Perform and maintains $27 price target.
RBC Capital Reiterates Sector Perform on Beam Therapeutics, Maintains $27 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.